Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Enters Integrated Alliance with AstraZeneca

Published: Monday, October 21, 2013
Last Updated: Monday, October 21, 2013
Bookmark and Share
Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease.

Evotec AG announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. 

Under the terms of this licence and collaboration agreement, AstraZeneca will receive access to a selected series of molecules identified in a screening effort, which is part of Evotec’s systematic kidney disease initiative. This particular programme has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca will provide industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities.

The agreement between Evotec and AstraZeneca triggers an undisclosed upfront payment as well as pre-clinical, clinical and regulatory milestones. Evotec is also eligible for additional milestone and royalty payments related to commercialisation. Evotec will receive research funding for work that will be conducted in collaboration with AstraZeneca. Specific financial details were not disclosed.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Exploring novel mechanisms and novel targets in the field of kidney disease is a logical next step for Evotec. We are very excited about AstraZeneca joining one of our programmes. AstraZeneca is a great partner sharing not only our vision but making valuable contributions beyond in an integrated discovery and development process.”

Dr Marcus Schindler, Head of Cardiovascular and Metabolic Diseases iMed, AstraZeneca, added: “Cardiovascular and metabolic diseases (CVMD) represents one of the three core areas for AstraZeneca. Within CVMD, we are committing significant efforts on research and development of potential new treatments for diabetic nephropathy, end-stage as well as chronic kidney disease. Our goal is to identify and develop effective therapies to halt or slow down the decline of renal function for patients suffering from kidney diseases. This new collaboration complements our research efforts in the renal disease space. Evotec has built a leading drug discovery platform in the field of kidney diseases and is well-positioned to work with us to generate highly innovative drug candidates so that we can accelerate the delivery of new medicines to patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec AG Increases Its Revenue Guidance For 2015
All other elements of the Company’s financial guidance as of 12 May 2015 are confirmed.
Tuesday, September 15, 2015
Evotec Enters into Agreement with Pfizer
Licence and collaboration agreement in the field of tissue fibrosis.
Friday, September 11, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec & Facio Partner
Facio partners with Evotec and initiates FSHD drug discovery programme.
Friday, May 08, 2015
Evotec and C4XD Enter Collaboration
Collaboration leverages the breadth & experience of Evotec's drug discovery infrastructure across chemistry & biology.
Tuesday, January 20, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of € 1.0 m.
Thursday, June 19, 2014
Evotec to Establish an Anti-infectives Platform with the Acquisition of Euprotec Ltd
Adds key know-how and infectious disease therapeutic area capabilities.
Thursday, May 29, 2014
Evotec Acquires UK-Based CRO Euprotec
Company announce the acquisition of all shares in Euprotec Ltd, a recognised leader in anti-infective drug discovery services
Thursday, May 29, 2014
Evotec Receives First Milestone in Roche Biomarker Collaboration
Evotec AG announce the successful achievement of a milestone in its biomarker alliance with Roche.
Thursday, April 24, 2014
Scientific News
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!